Grant of Awards

Oxford Biomedica PLC

08 April 2026

 

OXB

Grant of Awards

Oxford, UK - 08 April 2026: OXB (LSE: OXB) (the "Company"), a quality and innovation-led cell and gene therapy CDMO, announces that on 07 April 2026, nil-cost share options over ordinary shares of 50 pence each in the Company were granted under the Company's 2024 Long Term Incentive Plan ("LTIP"), including Restricted Share Units ("RSU") and the Company's 2024 Deferred Bonus Plan ("DBP").

As detailed in the recently published 2025 Directors' Remuneration Report:-

Re-instated LTIP awards: the LTIP grants in respect of 2024 and 2025, detailed below, reinstate the originally intended grant level for Dr. Frank Mathias and Dr. Lucinda Crabtree's 2024 and 2025 LTIP awards. The 2024 and 2025 LTIP awards were scaled back, primarily to manage the headroom available under the OXB share plans. The re-instatement honors the terms on which Dr. Mathias and Dr. Crabtree were recruited and reflects the Company's performance detailed in the 2025 Annual report and accounts. The re-instated LTIP awards remain subject to the original performance conditions and post-vesting holding periods, ensuring that the vesting of the awards is subject to the sustained strong performance of the business.

LTIP - Grant in respect of 2026: The 2026 LTIP metrics are 60% revenue, 40% Operating EBITDA margin, with target ranges in each case assessed on a constant currency basis which is set out in the Company's Directors' Remuneration Report for 2025.

Type	Name of individual	Title	Number of share options granted
LTIP - Grant in respect of 2026	Dr. Frank Mathias	Chief Executive Officer	478,119
LTIP - Grant in respect of 2025			46,195
LTIP - Grant in respect of 2024			43,790
2026 DBP	Dr. Frank Mathias	Chief Executive Officer	71,891
LTIP - Grant in respect of 2026	Dr. Lucinda Crabtree	Chief Financial Officer	156,884
LTIP - Grant in respect of 2025			26,526
LTIP - Grant in respect of 2024			12,876
2026 DBP	Dr. Lucinda Crabtree	Chief Financial Officer	47,179
LTIP - Grant in respect of 2026	Natalie Walter	Chief Legal Officer and Group Company Secretary	75,479
2026 DBP	Natalie Walter	Chief Legal Officer and Group Company Secretary	12,459
LTIP - Grant in respect of 2026	Dr. Kyriacos Mitrophanous	Chief Innovation Officer	72,391
2026 DBP	Dr. Kyriacos Mitrophanous	Chief Innovation Officer	10,841
LTIP - Grant in respect of 2026	Lisa Doman	Chief People Officer	69,992
2026 DBP	Lisa Doman	Chief People Officer	10,629
LTIP - Grant in respect of 2026	Dr. Sébastien Ribault	Chief Business Officer	107,102
2026 DBP	Dr. Sébastien Ribault	Chief Business Officer	14,908
LTIP - Grant in respect of 2026	Mark Caswell	Site Head, UK Operations	49,431
2026 LTIP RSU	Dr. Sabine Sydow	Chief of Staff	7,036
2026 LTIP RSU	Dr. Melanie Kearney	Global Head of Quality	12,711
2026 LTIP RSU	John Foy	Site Head, Durham Operations	12,380
2026 LTIP RSU	Stéphanie Colloud	Site Head and General Manager of France Operations	10,357
2026 LTIP RSU	Kathleen Miller	Head of Human Resources (and acting Interim Site Head, Bedford)	12,628

1.	Details of the Issuer or emission allowance market participant
a)	Full name of the entity	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
2.	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification / amendment	Initial Notification
3.	Details of the person discharging managerial responsibilities / person closely associated
a)	Is this a PDMR or PCA Submission	Submission for PDMR
b)	Name of natural person	Frank Mathias
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Date of the transaction	2026-04-07
b)	Description of instrument	Share
c)	Identification code	ISIN: GB00BDFBVT43
d)	Place of the transaction	Outside the trading venue
e)	Currency	GBP - British Pound
f)	Nature of the transaction	Grant of LTIP awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards.
g)	Price(s) and volumes(s)	Award Price Volume LTIP grant in respect of 2026 Nil 478,119 LTIP grant in respect of 2025 Nil 46,195 LTIP grant in respect of 2024 Nil 43,790
h)	Aggregated information
	-       Aggregated volume	LTIP awards granted over 478,119 shares in total
	-       Price -       Aggregated volume -       -       Price -       Aggregated volume -       Price	Nil LTIP awards over 46,195 shares in total Nil LTIP awards over 43,790 shares in total Nil

1.	Details of the Issuer or emission allowance market participant
a)	Full name of the entity	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
2.	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification / amendment	Initial Notification
3.	Details of the person discharging managerial responsibilities / person closely associated
a)	Is this a PDMR or PCA Submission	Submission for PDMR
b)	Name of natural person	Frank Mathias
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Date of the transaction	2026-04-07
b)	Description of instrument	Share
c)	Identification code	ISIN: GB00BDFBVT43
d)	Place of the transaction	Outside the trading venue
e)	Currency	GBP - British Pound
f)	Nature of the transaction	Grant of DBP award over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of the award.
g)	Price(s) and volumes(s)	Award Price Volume DBP grant in respect of 2026 Nil 71,891
h)	Aggregated information
	-       Aggregated volume	DBP awards granted over 71,891 shares in total
	-       Price	Nil

1.	Details of the Issuer or emission allowance market participant
a)	Full name of the entity	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
2.	Reason for the notification
a)	Position/status	Chief Financial Officer
b)	Initial notification / amendment	Initial Notification
3.	Details of the person discharging managerial responsibilities / person closely associated
a)	Is this a PDMR or PCA Submission	Submission for PDMR
b)	Name of natural person	Lucinda Crabtree
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Date of the transaction	2026-04-07
b)	Description of instrument	Share
c)	Identification code	ISIN: GB00BDFBVT43
d)	Place of the transaction	Outside the trading venue
e)	Currency	GBP - British Pound
f)	Nature of the transaction	Grant of LTIP awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards.
g)	Price(s) and volumes(s)	Award Price Volume LTIP grant in respect of 2026 Nil 156,884 LTIP grant in respect of 2025 Nil 26,526 LTIP grant in respect of 2024 Nil 12,876
h)	Aggregated information
	-       Aggregated volume	LTIP awards granted over 156,884 shares in total
	-       Price -       Aggregated volume -       -       Price -       Aggregated volume -       Price	Nil LTIP awards over 26,526 shares in total Nil LTIP awards over 12,876 shares in total Nil

1.	Details of the Issuer or emission allowance market participant
a)	Full name of the entity	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
2.	Reason for the notification
a)	Position/status	Chief Financial Officer
b)	Initial notification / amendment	Initial Notification
3.	Details of the person discharging managerial responsibilities / person closely associated
a)	Is this a PDMR or PCA Submission	Submission for PDMR
b)	Name of natural person	Lucinda Crabtree
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Date of the transaction	2026-04-07
b)	Description of instrument	Share
c)	Identification code	ISIN: GB00BDFBVT43
d)	Place of the transaction	Outside the trading venue
e)	Currency	GBP - British Pound
f)	Nature of the transaction	Grant of DBP award over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of the award.
g)	Price(s) and volumes(s)	Award Price Volume DBP grant in respect of 2026 Nil 47,179
h)	Aggregated information
	-       Aggregated volume	DBP awards granted over 47,179 shares in total
	-       Price	Nil

1.	Details of the Issuer or emission allowance market participant
a)	Full name of the entity	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
2.	Reason for the notification
a)	Position/status	Chief Legal Officer and Group Company Secretary
b)	Initial notification / amendment	Initial Notification
3.	Details of the person discharging managerial responsibilities / person closely associated
a)	Is this a PDMR or PCA Submission	Submission for PDMR
b)	Name of natural person	Natalie Walter
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Date of the transaction	2026-04-07
b)	Description of instrument	Share
c)	Identification code	ISIN: GB00BDFBVT43
d)	Place of the transaction	Outside the trading venue
e)	Currency	GBP - British Pound
f)	Nature of the transaction	Grant of LTIP awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards.
g)	Price(s) and volumes(s)	Award Price Volume LTIP grant in respect of 2026 Nil 75,479
h)	Aggregated information
	-       Aggregated volume	LTIP awards granted over 75,479 shares in total
	-       Price	Nil

1.	Details of the Issuer or emission allowance market participant
a)	Full name of the entity	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
2.	Reason for the notification
a)	Position/status	Chief Legal Officer and Group Company Secretary
b)	Initial notification / amendment	Initial Notification
3.	Details of the person discharging managerial responsibilities / person closely associated
a)	Is this a PDMR or PCA Submission	Submission for PDMR
b)	Name of natural person	Natalie Walter
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Date of the transaction	2026-04-07
b)	Description of instrument	Share
c)	Identification code	ISIN: GB00BDFBVT43
d)	Place of the transaction	Outside the trading venue
e)	Currency	GBP - British Pound
f)	Nature of the transaction	Grant of DBP award over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of the award.
g)	Price(s) and volumes(s)	Award Price Volume DBP grant in respect of 2026 Nil 12,459
h)	Aggregated information
	-       Aggregated volume	DBP awards granted over 12,459 shares in total
	-       Price	Nil

1.	Details of the Issuer or emission allowance market participant
a)	Full name of the entity	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
2.	Reason for the notification
a)	Position/status	Chief Business Officer
b)	Initial notification / amendment	Initial Notification
3.	Details of the person discharging managerial responsibilities / person closely associated
a)	Is this a PDMR or PCA Submission	Submission for PDMR
b)	Name of natural person	Sébastien Ribault
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Date of the transaction	2026-04-07
b)	Description of instrument	Share
c)	Identification code	ISIN: GB00BDFBVT43
d)	Place of the transaction	Outside the trading venue
e)	Currency	GBP - British Pound
f)	Nature of the transaction	Grant of LTIP awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards.
g)	Price(s) and volumes(s)	Award Price Volume LTIP grant in respect of 2026 Nil 107,102
h)	Aggregated information
	-       Aggregated volume	LTIP awards granted over 107,102 shares in total
	-       Price	Nil

1.	Details of the Issuer or emission allowance market participant
a)	Full name of the entity	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
2.	Reason for the notification
a)	Position/status	Chief Business Officer
b)	Initial notification / amendment	Initial Notification
3.	Details of the person discharging managerial responsibilities / person closely associated
a)	Is this a PDMR or PCA Submission	Submission for PDMR
b)	Name of natural person	Sébastien Ribault
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Date of the transaction	2026-04-07
b)	Description of instrument	Share
c)	Identification code	ISIN: GB00BDFBVT43
d)	Place of the transaction	Outside the trading venue
e)	Currency	GBP - British Pound
f)	Nature of the transaction	Grant of DBP award over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of the award.
g)	Price(s) and volumes(s)	Award Price Volume DBP grant in respect of 2026 Nil 14,908
h)	Aggregated information
	-       Aggregated volume	DBP awards granted over 14,908 shares in total
	-       Price	Nil

1.	Details of the Issuer or emission allowance market participant
a)	Full name of the entity	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
2.	Reason for the notification
a)	Position/status	Chief People Officer
b)	Initial notification / amendment	Initial Notification
3.	Details of the person discharging managerial responsibilities / person closely associated
a)	Is this a PDMR or PCA Submission	Submission for PDMR
b)	Name of natural person	Lisa Doman
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Date of the transaction	2026-04-07
b)	Description of instrument	Share
c)	Identification code	ISIN: GB00BDFBVT43
d)	Place of the transaction	Outside the trading venue
e)	Currency	GBP - British Pound
f)	Nature of the transaction	Grant of LTIP awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards.
g)	Price(s) and volumes(s)	Award Price Volume LTIP grant in respect of 2026 Nil 69,992
h)	Aggregated information
	-       Aggregated volume	LTIP awards granted over 69,992 shares in total
	-       Price	Nil

1.	Details of the Issuer or emission allowance market participant
a)	Full name of the entity	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
2.	Reason for the notification
a)	Position/status	Chief People Officer
b)	Initial notification / amendment	Initial Notification
3.	Details of the person discharging managerial responsibilities / person closely associated
a)	Is this a PDMR or PCA Submission	Submission for PDMR
b)	Name of natural person	Lisa Doman
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Date of the transaction	2026-04-07
b)	Description of instrument	Share
c)	Identification code	ISIN: GB00BDFBVT43
d)	Place of the transaction	Outside the trading venue
e)	Currency	GBP - British Pound
f)	Nature of the transaction	Grant of DBP award over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of the award.
g)	Price(s) and volumes(s)	Award Price Volume DBP grant in respect of 2026 Nil 10,629
h)	Aggregated information
	-       Aggregated volume	DBP awards granted over 10,629 shares in total
	-       Price	Nil

1.	Details of the Issuer or emission allowance market participant
a)	Full name of the entity	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
2.	Reason for the notification
a)	Position/status	Chief Innovation Officer
b)	Initial notification / amendment	Initial Notification
3.	Details of the person discharging managerial responsibilities / person closely associated
a)	Is this a PDMR or PCA Submission	Submission for PDMR
b)	Name of natural person	Kyriacos Mitrophanous
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Date of the transaction	2026-04-07
b)	Description of instrument	Share
c)	Identification code	ISIN: GB00BDFBVT43
d)	Place of the transaction	Outside the trading venue
e)	Currency	GBP - British Pound
f)	Nature of the transaction	Grant of LTIP awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards.
g)	Price(s) and volumes(s)	Award Price Volume LTIP grant in respect of 2026 Nil 72,391
h)	Aggregated information
	-       Aggregated volume	LTIP awards granted over 72,391 shares in total
	-       Price	Nil

1.	Details of the Issuer or emission allowance market participant
a)	Full name of the entity	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
2.	Reason for the notification
a)	Position/status	Chief Innovation Officer
b)	Initial notification / amendment	Initial Notification
3.	Details of the person discharging managerial responsibilities / person closely associated
a)	Is this a PDMR or PCA Submission	Submission for PDMR
b)	Name of natural person	Kyriacos Mitrophanous
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Date of the transaction	2026-04-07
b)	Description of instrument	Share
c)	Identification code	ISIN: GB00BDFBVT43
d)	Place of the transaction	Outside the trading venue
e)	Currency	GBP - British Pound
f)	Nature of the transaction	Grant of DBP award over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of the award.
g)	Price(s) and volumes(s)	Award Price Volume DBP grant in respect of 2026 Nil 10,841
h)	Aggregated information
	-       Aggregated volume	DBP awards granted over 10,841 shares in total
	-       Price	Nil

1.	Details of the Issuer or emission allowance market participant
a)	Full name of the entity	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
2.	Reason for the notification
a)	Position/status	Site Head, UK Operations
b)	Initial notification / amendment	Initial Notification
3.	Details of the person discharging managerial responsibilities / person closely associated
a)	Is this a PDMR or PCA Submission	Submission for PDMR
b)	Name of natural person	Mark Caswell
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Date of the transaction	2026-04-07
b)	Description of instrument	Share
c)	Identification code	ISIN: GB00BDFBVT43
d)	Place of the transaction	Outside the trading venue
e)	Currency	GBP - British Pound
f)	Nature of the transaction	Grant of LTIP awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards.
g)	Price(s) and volumes(s)	Award Price Volume LTIP grant in respect of 2026 Nil 49,431
h)	Aggregated information
	-       Aggregated volume	LTIP awards granted over 49,431 shares in total
	-       Price	Nil

1.	Details of the Issuer or emission allowance market participant
a)	Full name of the entity	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
2.	Reason for the notification
a)	Position/status	Chief of Staff
b)	Initial notification / amendment	Initial Notification
3.	Details of the person discharging managerial responsibilities / person closely associated
a)	Is this a PDMR or PCA Submission	Submission for PDMR
b)	Name of natural person	Sabine Sydow
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Date of the transaction	2026-04-07
b)	Description of instrument	Share
c)	Identification code	ISIN: GB00BDFBVT43
d)	Place of the transaction	Outside the trading venue
e)	Currency	GBP - British Pound
f)	Nature of the transaction	Grant of LTIP RSU awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards.
g)	Price(s) and volumes(s)	Award Price Volume LTIP RSU grant in respect of 2026 Nil 7,036
h)	Aggregated information
	-       Aggregated volume	LTIP RSU awards granted over 7,036 shares in total
	-       Price	Nil

1.	Details of the Issuer or emission allowance market participant
a)	Full name of the entity	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
2.	Reason for the notification
a)	Position/status	Global Head of Quality
b)	Initial notification / amendment	Initial Notification
3.	Details of the person discharging managerial responsibilities / person closely associated
a)	Is this a PDMR or PCA Submission	Submission for PDMR
b)	Name of natural person	Melanie Kearney
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Date of the transaction	2026-04-07
b)	Description of instrument	Share
c)	Identification code	ISIN: GB00BDFBVT43
d)	Place of the transaction	Outside the trading venue
e)	Currency	GBP - British Pound
f)	Nature of the transaction	Grant of LTIP RSU awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards.
g)	Price(s) and volumes(s)	Award Price Volume LTIP RSU grant in respect of 2026 Nil 12,711
h)	Aggregated information
	-       Aggregated volume	LTIP RSU awards granted over 12,711 shares in total
	-       Price	Nil

1.	Details of the Issuer or emission allowance market participant
a)	Full name of the entity	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
2.	Reason for the notification
a)	Position/status	Site Head, Durham Operations
b)	Initial notification / amendment	Initial Notification
3.	Details of the person discharging managerial responsibilities / person closely associated
a)	Is this a PDMR or PCA Submission	Submission for PDMR
b)	Name of natural person	John Foy
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Date of the transaction	2026-04-07
b)	Description of instrument	Share
c)	Identification code	ISIN: GB00BDFBVT43
d)	Place of the transaction	Outside the trading venue
e)	Currency	GBP - British Pound
f)	Nature of the transaction	Grant of LTIP RSU awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards.
g)	Price(s) and volumes(s)	Award Price Volume LTIP RSU grant in respect of 2026 Nil 12,380
h)	Aggregated information
	-       Aggregated volume	LTIP RSU awards granted over 12,380 shares in total
	-       Price	Nil

1.	Details of the Issuer or emission allowance market participant
a)	Full name of the entity	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
2.	Reason for the notification
a)	Position/status	Site Head and General Manager of France Operations
b)	Initial notification / amendment	Initial Notification
3.	Details of the person discharging managerial responsibilities / person closely associated
a)	Is this a PDMR or PCA Submission	Submission for PDMR
b)	Name of natural person	Stephanie Colloud
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Date of the transaction	2026-04-07
b)	Description of instrument	Share
c)	Identification code	ISIN: GB00BDFBVT43
d)	Place of the transaction	Outside the trading venue
e)	Currency	GBP - British Pound
f)	Nature of the transaction	Grant of LTIP RSU awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards.
g)	Price(s) and volumes(s)	Award Price Volume LTIP RSU grant in respect of 2026 Nil 10,357
h)	Aggregated information
	-       Aggregated volume	LTIP RSU awards granted over 10,357 shares in total
	-       Price	Nil

1.	Details of the Issuer or emission allowance market participant
a)	Full name of the entity	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
2.	Reason for the notification
a)	Position/status	Head of Human Resources (and acting Interim Site Head, Bedford)
b)	Initial notification / amendment	Initial Notification
3.	Details of the person discharging managerial responsibilities / person closely associated
a)	Is this a PDMR or PCA Submission	Submission for PDMR
b)	Name of natural person	Kathleen Miller
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Date of the transaction	2026-04-07
b)	Description of instrument	Share
c)	Identification code	ISIN: GB00BDFBVT43
d)	Place of the transaction	Outside the trading venue
e)	Currency	GBP - British Pound
f)	Nature of the transaction	Grant of LTIP RSU awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards.
g)	Price(s) and volumes(s)	Award Price Volume LTIP RSU grant in respect of 2026 Nil 12,628
h)	Aggregated information
	-       Aggregated volume	LTIP RSU awards granted over 12,628 shares in total
	-       Price	Nil

-Ends-

Enquiries:       

OXB:

Natalie Walter, Chief Legal Officer and Group Company Secretary - T: [phone] / E: [e-mail]

ICR Healthcare:

T: [phone] / E: [e-mail]

Mary-Jane Elliott / Angela Gray / Davide Salvi

About OXB

OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.

OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube.

 

END